Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Depreciation (2016)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Depreciation for 2 consecutive years, with $3.3 million as the latest value for Q2 2016.

  • For Q2 2016, Accumulated Depreciation changed N/A year-over-year to $3.3 million; the TTM value through Jun 2016 reached $3.3 million, changed N/A, while the annual FY2015 figure was $2.9 million, N/A changed from the prior year.
  • Accumulated Depreciation hit $3.3 million in Q2 2016 for Cartesian Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $3.3 million in Q2 2016 and bottomed at $2.9 million in Q4 2015.